CMV Immunity Monitoring in Lung Transplant Recipients

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-99
SponsorNYU Langone Health

About this trial

The purpose of this study is to determine the safety and feasibility of using a laboratory test to guide duration of antiviral prophylaxis with valganciclovir (medication used to prevent viral infections) after lung transplant. The laboratory test, inSIGHT™ CMV T Cell Immunity Panel, measures patients' immune response to a common viral infection known as cytomegalovirus (CMV). The goal of this study will be to safely decrease how long patients need to take valganciclovir based on the results of the CMV T Cell Immunity Panel.

Eligibility criteria

Qualifiers

Received a lung transplant, or multi-organ transplant involving a lung at NYU Langone Health

Pre-existing serological immunity to CMV (R+)

Able and willing to provide informed consent

Disqualifiers

Anti-thymocyte globulin induction immunosuppression

Perioperative desensitization

Pregnant or breastfeeding women

Trial design

Treatments tested in this trial

  • Cytomegalovirus T Cell Immunity Panel (CMV-TCIP)
  • Donor-Derived Cell-Free DNA (dd-cfDNA) Assay
  • Valganciclovir

Treatment groups

50 Participants
are divided into 1 treatment group

Sponsors and collaborators

NYU Langone Health

Lead sponsor

Viracor Eurofins

Collaborator